All IndicationsCardiovascularPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2
❤️
Heart Failure
4
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
CYAD
Celyad Oncology SA
Injection of C3BS-CQR-1
CYAD
Celyad Oncology SA
C3BS-CQR-1
JNJ
Johnson & Johnson
JNJ-39588146 5 ng/kg/min
NVO
Novo Nordisk A/S
CDR132L
HSCSW
HeartSciences Inc.
Nebulized Sodium Nitrite
JNJ
Johnson & Johnson
JNJ-39588146/min
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CYAD Celyad Oncology SA | Injection of C3BS-CQR-1 | Phase 3 | — | — | — |
| CYAD Celyad Oncology SA | C3BS-CQR-1 | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | JNJ-39588146 5 ng/kg/min | Phase 2 | — | — | — |
| NVO Novo Nordisk A/S | CDR132L | Phase 2 | — | — | — |
| HSCSW HeartSciences Inc. | Nebulized Sodium Nitrite | Phase 2 | — | — | — |
| JNJ Johnson & Johnson | JNJ-39588146/min | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.